Anticoagulant Anti Platelet Fibrinolytic Drugs08 Black and White
Anticoagulant Anti Platelet Fibrinolytic Drugs08 Black and White
Anticoagulant Anti Platelet Fibrinolytic Drugs08 Black and White
Antiplatelet Drugs
Introduction to Pharmacology I
Kishore Pasumarthi
([email protected])
Oct 29, 2008
• A blood
bl d clot
l t can occlude
l d bl
blood
d flflow causing
i iischemia
h i iin
various organs such as heart, brain and kidney.
- this can lead to:
• Abblood
ood cclot
o formed
o ed in oone
e ssite
e ca
can b
break
ea ooff a
and
d travel
a e
to remote sites and occlude smaller blood vessels. This
process is called thromboembolism.
Blood Clotting
• Highly regulated process involving platelets as
well as various cellular and blood clotting factors.
1) Thrombogenesis
2) Blood coagulation
Thrombogenesis
• Platelet adhesion and aggregation:
• Platelet plug:
• Fibrin
Fib i RReinforcement:
i f t
Vessel wall Collagen Endothelium
damage
ADP
Platelet 1) Platelet adhesion
TXA2
5-HT and aggregation
Platelet 2) Formation of weak
+ platelet
l t l t plug
l
Platelet
3) Fibrin
Extrinsic Intrinsic Reinforcement
Xa
+
+ Fibrin
+ Blood
Prothrombin Thrombin
Coagulation
Fibrinogen
Blood Clot
• Intrinsic pathway
– activated
acti ated by
b surface
s rface contact with
ith a foreign body
bod
Schematic of Blood Coagulation
Tissue injury
Abnormal
vessel wall
Extrinsic
XIIa XII
Intrinsic
VII + TF VIIa XIa XI
Ix IXa IX
X Xa
II IIa
Prothrombin Thrombin
I Ia
Fibrinogen Fibrin Clot
NOT ON EXAM
Anticoagulant Drugs
• Heparin (Enoxaparin) (LMWH):
• Binds to and stabilizes antithrombin which inhibits many
clotting factor proteases (1000x enhanced activity)
• 1st line therapy (acts quickly)
• Administration
Administration: by
b II.V.
V or S
S.C.
C injection
• Indications: embolisms, prophylactic (low dose
SC)
S.C.),
• Toxicity: excessive bleeding therefore closely
monitor especially in elderly and renal failure
monitor,
patients, thrombocytopenia occurs in 25% or
more of patients
p
• Antidote: protamine sulfate a specific antagonist
Extrinsic
E i i Intrinsic
clotting cascade clotting cascade
Xa
Heparin
Prothrombin Thrombin
Antithrombin
Fibrinogen Fibrin Clot 1000X
Anticoagulant Drugs
• Hirudin
– Specific irreversible thrombin inhibitor isolated from
the leech available as recombinant form (lepirudin)
Xa
Prothrombin Hirudin
Thrombin
– Antidote: vitamin K
Mechanism of Warfarin Action
Descarboxy-
b CO2
prothrombin carboxylase Prothrombin
Coupled
Active
A i Inactive
Vitamin K O2 vitamin K
(catalyst)
y
Epoxide
p
Antidote: hydrolase
Vitamin K
Supplementation
Warfarin
Regulation of Coagulation
Plasminogen
Aminocaproic acid
t-PA, urokinase +
Plasmin
• Urokinase
– Human
H enzyme converts
t plasminogen
l i tto plasmin
l i
• very expensive, thousands of dollars
• Alteplase
– recombinant human t-PA (tissue plasminogen
activators)
Fibrinolytic Drugs (cont)
• MOA:
– Lyse thrombi by catalyzing the formation of plasmin
– t-PA
t PA preferentially activates plasminogen bound to
fibrin confining fibrinolysis to formed thrombus avoids
systemic activation
• Administration: I.V. (5
( min-12 hrs))
• Indications:
– multiple
lti l pulmonary
l emboli,
b li central
t ld deep vein
i
thrombosis
– acute myocardial infarction (can reduce mortality by
20% in MI patients)
– patients presenting with acute stroke symptoms given
within 3 hours of onset
• Toxicity: allergies and bleeding
Platelet Function
• Platelet function can be regulated 3 ways:
1) autocrine
t i stimulation
ti l ti - made d bby platelets
l t l t tto
interact with their own receptors (ADP, PG, 5-
HT etc.)
etc )
2) agents made by platelets which function
cAMP Ca2+ etc.)
internally (TXA2, cAMP, etc )
3) external agents that interact with their
membrane receptors (Collagen, thrombin,
prostacyclin)
ADP
Platelet 1) Platelet adhesion
TXA2
5-HT and aggregation
Platelet 2) Formation of weak
+ platelet
l t l t plug
l
Platelet
3) Fibrin
Extrinsic Intrinsic Reinforcement
Xa
+
+ Fibrin
+ Blood
Prothrombin Thrombin
Coagulation
Fibrinogen
Antiplatelet Drugs
• Aspirin (acetylsalicylic acid)
• Indications: Prophylaxis
p y of MI ((350mg/d)
g )
Platelet
GP
IIb/IIIa
Fibrinogen
Platelet
Vessel wall Collagen Endothelium
damage
ADP vWF
TXA2 Platelet
5-HT
Antiplatelet drugs
(Aspirin,
Thienopyridines,
GPIIb/III bl
GPIIb/IIIa blockers)
k )
+
Platelet
Arterial Thrombosis